Meet the AMR Action Fund Team
Henry Skinner, PhD, MJur
Chief Executive Officer
Henry Skinner, PhD, MJur
Chief Executive Officer
Henry Skinner, PhD, MJur, is an experienced executive who is deeply versed in the economic and scientific challenges of antimicrobial drug development.
Prior to joining the Fund, he held leadership positions across the pharmaceutical and venture capital sectors, including serving as Senior Vice President, Venture at Tekla Capital Management and as Deputy Head and Managing Director of the Novartis Venture Fund. In addition, Henry was the CEO of SelectX Pharmaceuticals, which focused on developing small-molecule antimicrobials, and NeoGenesis Pharmaceuticals, which developed a platform for identifying and optimizing drug candidates.
Over the years, he has held Business Development positions at the Novartis Institutes for Biomedical Research, Pfizer, Pharmacia, Pharmacia & Upjohn, and Lexicon Genetics. Henry was a postdoctoral fellow at Baylor College of Medicine in the department of Human and Molecular Genetics. He earned a PhD in Microbiology and an MS in Biochemistry from the University of Illinois; an MJur in Health Law, Policy, and Management from Texas A&M; and an MS and a BS in Biology/Biotechnology from Worcester Polytechnic Institute.
Martin Heidecker, PhD, MBA
Chief Investment Officer
Martin Heidecker, PhD, MBA
Chief Investment Officer
Bill Burns
Board Chair
Bill Burns
Board Chair
Sergei Petukhov, DVM
Managing Director
Sergei Petukhov, DVM
Managing Director
Carly Levine, PhD
Venture Analyst
Carly Levine, PhD
Venture Analyst
John Alter, MBA
Head of External Affairs
John Alter, MBA
Head of External Affairs
Deepali Patel, MPH
Director of International Policy
Deepali Patel, MPH
Director of International Policy
Jaclyn Levy, MS
Director of U.S. Policy
Jaclyn Levy, MS
Director of U.S. Policy
Chris Sweeney, MSJ
Communications Director
Chris Sweeney, MSJ
Communications Director
